Buy Actemra 400 Tocilizumab

Actemra 400 (tocilizumab) is an injectable medication used for inflammatory conditions. This 400mg/20ml vial form supports immune response modulation. Find Actemra 400mg/20ml for prescription-based treatment plans. Suitable for adults managing chronic inflammatory diseases.

Strength

400mg/20ml

Manufacturer / TM Owner

Hoffmann La Roche Ltd.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

Actemra 400 (tocilizumab) is used to treat moderate to severe rheumatoid arthritis in adults. It helps reduce inflammation and joint damage when other treatments haven’t worked. This medication is also prescribed for giant cell arteritis and systemic juvenile idiopathic arthritis in certain patients. Actemra works by targeting specific pathways in the immune system.

Side Effects

Actemra 400 may help reduce joint pain and swelling associated with inflammatory conditions. Users often report improved mobility and reduced stiffness over time. Some may experience changes in energy levels or reduced fever in inflammatory flare-ups. Individual responses vary based on condition and treatment plan.

Precautions & Warnings

Store Actemra 400 vials at 2°C to 8°C and protect from light. Do not freeze or shake vigorously. Always check the vial for particles or discoloration before use. Dispose of used needles and vials properly according to local regulations. Keep out of reach of children and pets.

Avoid Interactions

Actemra may interact with other immunosuppressants or live vaccines, increasing infection risk. Caution is advised when combining with CYP3A4 inhibitors or inducers, as they may affect tocilizumab levels. Avoid alcohol during treatment, as it may worsen certain side effects. Always inform your healthcare provider about all medications you take.

References

Frequently Asked Questions

Actemra 400 (tocilizumab) is primarily used to treat rheumatoid arthritis and certain inflammatory conditions.

Actemra 400 is given as an injection under medical supervision, typically in a clinic or hospital setting.

Actemra 400 requires a prescription and is available through licensed pharmacies or healthcare providers.

Common effects may include injection site reactions, headache, or upper respiratory infections.

Consult your healthcare provider; the safety of tocilizumab during pregnancy has not been fully established.

Published by GNH India Pharmaceuticals Limited

Last updated: 18 May 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.